Elvitegravir Production Cost Reports

The report provides a detailed analysis essential for establishing an Elvitegravir production plant. It encompasses all critical aspects necessary for Elvitegravir production, including the cost of Elvitegravir production, Elvitegravir plant cost, Elvitegravir production costs, and the overall Elvitegravir production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating an Elvitegravir production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Elvitegravir is a medication used to treat HIV-1 infection in adults who have already had treatment for the virus. To increase its efficacy, it is frequently administered in combination with other medications, such as ritonavir and a protease inhibitor. Patients who have already used HIV drugs can benefit from this treatment, which is designed to help them better control their illness. It is a type 1 HIV (human immunodeficiency virus) integrase strand transfer inhibitor.

The procurement of Elvitegravir is influenced by its application in the pharmaceutical and medical industries as an antiretroviral medication used to treat HIV-1 infection. The need for Elvitegravir is increasing as cases of HIV-1 infections are on the rise. The increasing awareness among individuals towards HIV infections and antiviral therapy is yet another factor that increases the need for Elvitegravir. Because of the improvement in health facilities, antiviral drugs are easily accessible to patients, and this has increased the options for patients.

Elvitegravir is used with other antiretroviral drugs in combination therapy to treat HIV-1 infection, which increases its demand. When paired with active background therapy, Elvitegravir generates virologic suppression that is both quick and lasting. Trials examining the effectiveness of co-formulated Elvitegravir/cobicistat/emtricitabine/tenofovir (EVG/COBI/FTC/TDF) once daily show a high rate of virologic suppression with fewer side effects related to the central nervous system and psyche. Overall, industrial Elvitegravir procurement is influenced by its application in the pharmaceutical and medical industries, rising cases of HIV infections, improved healthcare facilities, its use with other drugs, fewer side effects, quick action, increasing access to antiretroviral drugs, and regulatory approvals.

Raw Material for Elvitegravir Production

According to the Elvitegravir production plant project report, the key raw material used in the production of Elvitegravir includes 2,4-dimethoxyacetophenone.

Manufacturing Process of Elvitegravir

The extensive Elvitegravir production cost report consists of the following major industrial production process:

• Production from 2,4-dimethoxyacetophenone: The production process of Elvitegravir starts with the halogenation of the starting compound at the 5th position to form 5-haloacetophenone. The compound then undergoes condensation with dialkyl carbonate to form the corresponding benzoylacetate. The compound is then treated with N,N-dimethylformamide dimethyl acetal followed by (S)-valinol, which then gives the corresponding intermediate benzoyl acrylate. The next step is the nucleophilic substitution reaction of the 2-methoxy group by treatment with N,O-bis(trimethylsilyl)-acetamide to form 1,4-dihydroquinolin-4-oxo derivative, protecting the OH group as the trimethylsilyl derivative. Finally, 2-fluoro-3-chlorobenzylzinc bromide is subjected to Negishi coupling followed by hydrolysis to produce Elvitegravir.

Elvitegravir, commercially known as Genvoya, is a white to off-white crystalline powder having the molecular formula C23H23ClFNO5 and a molecular weight of 447.9 g/mol. It has a limited water solubility of 0.00652 mg/mL. It dissolves to some extent in DMSO and methanol. It has a log P value of around 3.66. The value of its dissociation constant, pKa, is 5.97. It has a melting point in the range of 93-96 °C. It is a type 1 HIV (human immunodeficiency virus) integrase strand transfer inhibitor used to treat HIV-1 infection.